PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism

PET Clinics

Volumn 2, Issue 3, 2007, Pages 351-375

  Prasad, Vikas ^a   Ambrosini, Valentina ^b   Alavi, Abass ^c   Fanti, Stefano ^b   Baum, Richard P ^a  

^a ZENTRALKLINIK BAD BERKA   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

F 18 DOPA; Ga 68; Neuroendocrine tumors; PET CT; Somatostatin receptor imaging

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 1 3 BETA NAPHTHYLALANINE 8 THREONINE OCTREOTIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 BETA NAPHTHYLALNINE OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE OCTREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE OCTREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE; 6 FLUORODOPA F 18; ANGIOPEPTIN; BIOCHEMICAL MARKER; DOPA; DOPA CARBON 11; EPHEDRINE CARBON 11; EPINEPHRINE CARBON 11; FLUORODEOXYGLUCOSE F 18; FLUORODOPAMINE F 18; GALLIUM 68; HYDROXYEPHIDRINE CARBON 11; HYDROXYEPIPHEDRINE CARBON 11; OCTREOSCAN IN 111; OCTREOTIDE; PENTETIC ACID; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; RECEPTOR; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE;

CANCER SURGERY; CHEMOEMBOLIZATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; FOLLOW UP; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LOCALIZATION;

EID: 64749095001     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2008.04.007     Document Type: Review

References (84)

1. Oberndorfer S. Karzinoidtumore des Dünndarms. Frankf Z Pathol 1 (1907) 426-429
2. Vinik A.I., Woltering E.A., O'Dorisio T.M., et al. Neuroendocrine tumors: a comprehensive guide to diagnosis and management (2006), Inter Science Institute
3. Jensen R.T. Endocrine tumors of the gastrointestinal tract and pancreas. In: Kasper D.L., Fauci A.S., Longo D.L., et al. (Eds). Harrison's principles of internal medicine. 16th edition (2005), McGraw-Hill 2347-2358
4. Schmitt-Gräff A., Hezel B., and Wiedenmann B. Pathologisch-diagnostische Aspekte neuroendokriner Tumoren des Gastrointestinaltrakts. Der Onkologe (2000) 613-623
5. Solcia E., Kloppel G., and Sobin L.H. Histological typing of tumors: international histological classification of tumors in collaboration with 9 pathologists from 4 countries. Organisation WHOPPWH. 2nd edition. (2000), Springer, Berlin (Germany)
6. Rindi G., Kloppel G., Alhman H., et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449 (2006) 395-401
7. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24 (2003) 389-427
8. Reubi J.C., Schar J.C., Waser B., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27 (2000) 273-282
9. Reubi J.C., Waser B., Schaer J.C., et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28 (2001) 836-846
10. Rufini V., Calcagni M.L., and Baum R.P. Imaging of neuroendocrine tumors. Semin Nucl Med 36 (2006) 228-247
11. Wild D., Macke H.R., Waser B., et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 32 (2005) 724
12. Wild D., Schmitt J.S., Ginj M., et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30 (2003) 1338-1347
13. Ginj M., Zhang H., Waser B., et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 103 (2006) 16436-16441
14. Reubi J.C., Schaer J.C., Wenger S., et al. SST3-selective potent peptidic somatostatin receptor antagonists. Proc Natl Acad Sci USA 97 (2000) 13973-13978
15. Rösch F., and Knapp W.H. Radionuclide generators vol. 4 (2003), Kluwer Academic Publishers, Rotterdam (The Netherlands)
16. Zhernosekov K.P., Filosofov D.V., Baum R.P., et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 48 (2007) 1741-1748
17. Meyer G.J., Macke H., Schuhmacher J., et al. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 31 (2004) 1097-1104
18. Moody T.W., Hill J.M., and Jensen R.T. VIP as a trophic factor in the CNS and cancer cells. Peptides 24 (2003) 163-177
19. Reubi J.C., and Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30 (2003) 781-793
20. Thakur M.L., Marcus C.S., Saeed S., et al. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med 41 (2000) 107-110
21. Virgolini I., Kurtaran A., Raderer M., et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 36 (1995) 1732-1739
22. Virgolini I., Raderer M., Kurtaran A., et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 331 (1994) 1116-1121
23. Behe M., Becker W., Gotthardt M., et al. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 30 (2003) 1140-1146
24. Behr T.M., Behe M., Angerstein C., et al. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 5 (1999) 3124s-3138s
25. Behr T.M., Jenner N., Radetzky S., et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 25 (1998) 424-430
26. Breeman W.A., De Jong M., Bernard B.F., et al. Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 83 (1999) 657-663
27. Kwekkeboom D.J., Bakker W.H., Kooij P.P., et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 27 (2000) 1312-1317
28. Reubi J.C., Waser B., Schaer J.C., et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 25 (1998) 481-490
29. Eriksson B., Bergstrom M., Orlefors H., et al. Use of PET in neuroendocrine tumors: in vivo applications and in vitro studies. Q J Nucl Med 44 (2000) 68-76
30. Orlefors H., Sundin A., Ahlstrom H., et al. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol 16 (1998) 2534-2541
31. Eidelberg D., Moeller J.R., Dhawan V., et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 5 (1990) 203-213
32. Ribeiro M.J., Boddaert N., Bellanne-Chantelot C., et al. The added value of [(18)F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children. Eur J Nucl Med Mol Imaging 34 (2007) 2120-2128
33. Creveling C.R., and Kirk K.L. The effect of ring-fluorination on the rate of O-methylation of dihydroxyphenylalanine (DOPA) by catechol-O-methyltransferase: significance in the development of 18F-PET scanning agents. Biochem Biophys Res Commun 130 (1985) 1123-1131
34. Melega W.P., Luxen A., Perlmutter M.M., et al. Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats. Biochem Pharmacol 39 (1990) 1853-1860
35. Eldrup E., Clausen N., Scherling B., et al. Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma. Scand J Clin Lab Invest 61 (2001) 479-490
36. Hoegerle S., Altehoefer C., Ghanem N., et al. Whole-body 18F DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology 220 (2001) 373-380
37. Kolby L., Bernhardt P., Levin-Jakobsen A.M., et al. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 89 (2003) 1383-1388
38. Koopmans K.P., de Vries E.G., Kema I.P., et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 7 (2006) 728-734
39. Timmers H.J., Hadi M., Carrasquillo J.A., et al. The effects of carbidopa on uptake of 6-18F-fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 48 (2007) 1599-1606
40. Hofmann M., Maecke H., Borner R., et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28 (2001) 1751-1757
41. Buchmann I., Henze M., Engelbrecht S., et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34 (2007) 1617-1626
42. Gabriel M., Decristoforo C., Kendler D., et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48 (2007) 508-518
43. Kowalski J., Henze M., Schuhmacher J., et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT: first results in patients with neuroendocrine tumors. Mol Imaging Biol 5 (2003) 42-48
44. Maecke H.R., Hofmann M., and Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med 46 Suppl 1 (2005) 172S-178S
45. Antunes P., Ginj M., Zhang H., et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging (2007) 982-993
46. Koukouraki S., Strauss L.G., Georgoulias V., et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33 (2006) 460-466
47. Meisetschlager G., Poethko T., Stahl A., et al. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med 47 (2006) 566-573
48. Anderson C.J., Dehdashti F., Cutler P.D., et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 42 (2001) 213-221
49. Lewis J.S., Lewis M.R., Cutler P.D., et al. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res 5 (1999) 3608-3616
50. Sprague J.E., Peng Y., Sun X., et al. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 10 (2004) 8674-8682
51. Wang M., Caruano A.L., Lewis M.R., et al. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res 63 (2003) 6864-6869
52. Becherer A., Szabo M., Karanikas G., et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 45 (2004) 1161-1167
53. Hoegerle S., Nitzsche E., Altehoefer C., et al. Pheochromocytomas: detection with 18F DOPA whole body PET: initial results. Radiology 222 (2002) 507-512
54. Nanni C., Fanti S., and Rubello D. 18F-DOPA PET and PET/CT. J Nucl Med 48 (2007) 1577-1579
55. Reubi J.C., Chayvialle J.A., Franc B., et al. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 64 (1991) 567-573
56. Hoegerle S., Altehoefer C., Ghanem N., et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28 (2001) 64-71
57. Beuthien-Baumann B., Strumpf A., Zessin J., et al. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 34 (2007) 1604-1609
58. Crippa F., Alessi A., Gerali A., et al. FDG-PET in thyroid cancer. Tumori 89 (2003) 540-543
59. Mackenzie I.S., Gurnell M., Balan K.K., et al. The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol 157 (2007) 533-537
60. Hoegerle S., Ghanem N., Altehoefer C., et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30 (2003) 689-694
61. Jacob T., Grahek D., Younsi N., et al. Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results. Eur J Nucl Med Mol Imaging 30 (2003) 1266-1269
62. Adams S., Baum R., Rink T., et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25 (1998) 79-83
63. Pasquali C., Rubello D., Sperti C., et al. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?. World J Surg 22 (1998) 588-592
64. Scanga D.R., Martin W.H., and Delbeke D. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med 29 (2004) 86-90
65. Sundin A., Eriksson B., Bergstrom M., et al. PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci 1014 (2004) 246-257
66. Zhao D.S., Valdivia A.Y., Li Y., et al. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer. Semin Nucl Med 32 (2002) 272-275
67. Diehl M., Risse J.H., Brandt-Mainz K., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28 (2001) 1671-1676
68. Shulkin B.L., Wieland D.M., Baro M.E., et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 37 (1996) 16-21
69. Shulkin B.L., Wieland D.M., Schwaiger M., et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 33 (1992) 1125-1131
70. Abbruzzese J.L., Abbruzzese M.C., Lenzi R., et al. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13 (1995) 2094-2103
71. Didolkar M.S., Fanous N., Elias E.G., et al. Metastatic carcinomas from occult primary tumors: a study of 254 patients. Ann Surg 186 (1977) 625-630
72. Le Chevalier T., Cvitkovic E., Caille P., et al. Early metastatic cancer of unknown primary origin at presentation: a clinical study of 302 consecutive autopsied patients. Arch Intern Med 148 (1988) 2035-2039
73. Steckel R.J., and Kagan A.R. Diagnostic persistence in working up metastatic cancer with an unknown primary site. Radiology 134 (1980) 367-369
74. Naresh K.N. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site? A hypothesis. Med Hypotheses 59 (2002) 357-360
75. Raber M.N., Faintuch J., Abbruzzese J.L., et al. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. Ann Oncol 2 (1991) 519-520
76. Alberini J.L., Belhocine T., Hustinx R., et al. Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome). Nucl Med Commun 24 (2003) 1081-1086
77. Bohuslavizki K.H., Klutmann S., Kroger S., et al. FDG PET detection of unknown primary tumors. J Nucl Med 41 (2000) 816-822
78. Freudenberg L.S., Fischer M., Antoch G., et al. Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary. Med Princ Pract 14 (2005) 155-160
79. Gutzeit A., Antoch G., Kuhl H., et al. Unknown primary tumors: detection with dual-modality PET/CT: initial experience. Radiology 234 (2005) 227-234
80. Kole A.C., Nieweg O.E., Pruim J., et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 82 (1998) 1160-1166
81. Syed R., Bomanji J.B., Nagabhushan N., et al. Impact of combined (18)F-FDG PET/CT in head and neck tumours. Br J Cancer 92 (2005) 1046-1050
82. Ambrosini V., Tomassetti P., Rubello D., et al. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. Nucl Med Commun 28 (2007) 473-477
83. Pasquali C., Sperti C., Scappin S., et al. Role and indications of fluorodeoxyglucose positron emission tomography (FDG-PET) in neuroendocrine pancreatico-duodenal tumors. J pancreas 6 5 Suppl (2004) 528-529
84. Oh SW, Prasad V, Lee DS, et al. Monitoring response to peptide receptor radionuclide therapy (PRRT) in patients with metastasised neuroendocrine tumours (NET): intraindividual comparison between Ga-68-DOTA-NOC, F-18-FDG-PET/CT, and CT alone [abstract EPOS]. European Society of Radiology Conference. Vienna, March 7-11, 2008.